Rejoint received CE Mark approval for the complete extended range of sizes of the Rejoint YourKnee total knee replacement. The initial CE Mark approval was granted in 1Q20.
Rejoint offers more than 6,300 femoral variations including multiple designs and coatings. FDA 510(k) clearance is expected in 2Q21.
The YourKnee approach combines elements of 3D printing, patient-specific implants, artificial intelligence and wearables to design personalized implants, surgical simulation and post-op rehabilitation tools for every patient. YourKnee also includes an integrated system of dedicated wearables to remotely monitor and to track recovery and rehabilitation.
Rejoint received CE Mark approval for the complete extended range of sizes of the Rejoint YourKnee total knee replacement. The initial CE Mark approval was granted in 1Q20.
Rejoint offers more than 6,300 femoral variations including multiple designs and coatings. FDA 510(k) clearance is expected in 2Q21.
The YourKnee approach combines...
Rejoint received CE Mark approval for the complete extended range of sizes of the Rejoint YourKnee total knee replacement. The initial CE Mark approval was granted in 1Q20.
Rejoint offers more than 6,300 femoral variations including multiple designs and coatings. FDA 510(k) clearance is expected in 2Q21.
The YourKnee approach combines elements of 3D printing, patient-specific implants, artificial intelligence and wearables to design personalized implants, surgical simulation and post-op rehabilitation tools for every patient. YourKnee also includes an integrated system of dedicated wearables to remotely monitor and to track recovery and rehabilitation.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
